These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30635631)

  • 1. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
    Jawhar M; Döhner K; Kreil S; Schwaab J; Shoumariyeh K; Meggendorfer M; Span LLF; Fuhrmann S; Naumann N; Horny HP; Sotlar K; Kubuschok B; von Bubnoff N; Spiekermann K; Heuser M; Metzgeroth G; Fabarius A; Klein S; Hofmann WK; Kluin-Nelemans HC; Haferlach T; Döhner H; Cross NCP; Sperr WR; Valent P; Reiter A
    Leukemia; 2019 May; 33(5):1124-1134. PubMed ID: 30635631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
    Yui S; Kurosawa S; Yamaguchi H; Kanamori H; Ueki T; Uoshima N; Mizuno I; Shono K; Usuki K; Chiba S; Nakamura Y; Yanada M; Kanda J; Tajika K; Gomi S; Fukunaga K; Wakita S; Ryotokuji T; Fukuda T; Inokuchi K
    Ann Hematol; 2017 Oct; 96(10):1641-1652. PubMed ID: 28762080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
    Duan W; Liu X; Zhao X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Shi H; Chang Y; Liu K; Huang X; Qin Y; Jiang H
    Ann Hematol; 2021 May; 100(5):1203-1212. PubMed ID: 33474629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
    Naumann N; Jawhar M; Schwaab J; Kluger S; Lübke J; Metzgeroth G; Popp HD; Khaled N; Horny HP; Sotlar K; Valent P; Haferlach C; Göhring G; Schlegelberger B; Meggendorfer M; Hofmann WK; Cross NCP; Reiter A; Fabarius A
    Genes Chromosomes Cancer; 2018 May; 57(5):252-259. PubMed ID: 29341334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
    Schnittger S; Kohl TM; Haferlach T; Kern W; Hiddemann W; Spiekermann K; Schoch C
    Blood; 2006 Mar; 107(5):1791-9. PubMed ID: 16254134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
    Huh J; Kim HJ; Jung CW; Kim HJ; Kim SH; Kim YK; Kim HJ; Shin MG; Moon JH; Sohn SK; Kim SH; Lee WS; Won JH; Mun YC; Kim H; Park J; Min WS; Kim DH;
    Am J Hematol; 2012 Oct; 87(10):961-8. PubMed ID: 22886749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of the KIT
    Craig JW; Hasserjian RP; Kim AS; Aster JC; Pinkus GS; Hornick JL; Steensma DP; Coleman Lindsley R; DeAngelo DJ; Morgan EA
    Mod Pathol; 2020 Jun; 33(6):1135-1145. PubMed ID: 31896808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
    Tan Y; Liu Z; Wang W; Zhu G; Guo J; Chen X; Zheng C; Xu Z; Chang J; Ren F; Wang H
    Leuk Res; 2018 Jun; 69():89-93. PubMed ID: 29705537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
    Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
    Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic mastocytosis associated with t(8;21) acute myeloid leukemia in a child: detection of the D816A mutation of KIT.
    Yabe M; Masukawa A; Kato S; Yabe H; Nakamura N; Matsushita H
    Pediatr Blood Cancer; 2012 Dec; 59(7):1313-6. PubMed ID: 22847983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1.
    Srinivasan S; Dhamne C; Patkar N; Chatterjee G; Moulik NR; Chichra A; Pallath A; Tembhare P; Shetty D; Subramanian PG; Narula G; Banavali S
    Pediatr Blood Cancer; 2024 Feb; 71(2):e30791. PubMed ID: 38014874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.
    Fritsche-Polanz R; Fritz M; Huber A; Sotlar K; Sperr WR; Mannhalter C; Födinger M; Valent P
    Mol Oncol; 2010 Aug; 4(4):335-46. PubMed ID: 20471335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The impact of KIT and other concomitant gene mutations on the prognoses of patients with core-binding factor acute myeloid leukemia].
    Wang F; Wang W; Liu M; Zhang Y; Chen X; Yuan LL; Ma XL; Nie DJ; Wang MY; Zhang Y; Zhang W; Liu MY; Liu HX
    Zhonghua Yi Xue Za Zhi; 2020 Jan; 100(3):225-229. PubMed ID: 32008291
    [No Abstract]   [Full Text] [Related]  

  • 17. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.
    Richardson DR; Swoboda DM; Moore DT; Johnson SM; Chan O; Galeotti J; Esparza S; Hussaini MO; Van Deventer H; Foster MC; Coombs CC; Montgomery ND; Sallman DA; Zeidner JF
    Am J Hematol; 2021 Apr; 96(4):462-470. PubMed ID: 33502020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative analysis of prognostic factors in Chinese core binding factor leukemia.
    Wang D; Qiao C; Xiao M; Geng Z; Shang Z; He J; Huang M; Yang Y; Zhang N; Liu Y; Li J; Li C; Zhou J
    Biochem Biophys Res Commun; 2012 Nov; 428(3):411-5. PubMed ID: 23107788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
    Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
    Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
    Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
    Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.